Starling Oncology, Inc. (STLN) · Insider trading
What Starling Oncology's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$2.69M
1 insider, 16 trades
Sold, 12 months
$2.81M
5 insiders, 91% under a plan
Net, 12 months
−$122,183
bought less sold
Latest filing
2026-08-24
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| M33 Growth I L.P.Director, 10% owner | – | $28.41M | 6 | 2025-09-04 | 7,932,389 |
| Hively BradDirector | $97,091 | $7.75M | 8 | 2026-08-21 | 411,976 |
| Chernett Jorey10% owner | $2.69M | – | 16 | 2026-08-14 | 10,660,858 |
| Barasch Richard ADirector | $1.41M | – | 1 | 2025-03-26 | – |
| Kaushal MohitDirector | – | $335,016 | 2 | 2026-04-16 | 172,583 |
| Pacala Mark LDirector | $94,184 | $200,000 | 4 | 2025-11-18 | 222,811 |
| Podnos YaleChief Medical Officer | $9,418 | $276,524 | 4 | 2026-07-14 | 259,527 |
| Johnson Karen MarieDirector | $37,673 | – | 1 | 2025-03-26 | 203,409 |
| Virnich DanielChief Executive Officer | $23,546 | – | 1 | 2025-03-26 | 724,363 |
| Carter Robert RossChief Financial Officer | $9,418 | $879 | 2 | 2026-01-02 | 235,122 |
| Castle JeremyChief Operating Officer | $9,418 | – | 1 | 2025-03-26 | 90,386 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Hively BradDirector | Saleplan | 298,853 | 6.51 | $1.95M | 411,976 | Form 4 |
| 2026-08-14 | Chernett Jorey10% owner | Buy | 12,000 | 6.54 | $78,480 | 10,660,858 | Form 4 |
| 2026-07-21 | Chernett Jorey10% owner | Buy | 18,000 | 5.27 | $94,860 | 10,648,858 | Form 4 |
| 2026-07-14 | Podnos YaleChief Medical Officer | Saleplan | 17,974 | 6.43 | $115,573 | 259,527 | Form 4 |
| 2026-07-14 | Podnos YaleChief Medical Officer | Saleplan | 5,478 | 6.35 | $34,785 | 259,527 | Form 4 |
| 2026-07-10 | Chernett Jorey10% owner | Buy | 15,000 | 5.85 | $87,750 | 10,630,858 | Form 4 |
| 2026-06-23 | Chernett Jorey10% owner | Buy | 18,000 | 5.02 | $90,360 | 10,615,858 | Form 4 |
| 2026-06-08 | Podnos YaleChief Medical Officer | Saleplan | 23,451 | 5.38 | $126,166 | 259,527 | Form 4 |
| 2026-06-04 | Chernett Jorey10% owner | Buy | 12,000 | 4.75 | $57,000 | 10,579,858 | Form 4 |
| 2026-05-20 | Chernett Jorey10% owner | Buy | 33,500 | 4.07 | $136,345 | 10,567,858 | Form 4 |
| 2026-05-19 | Chernett Jorey10% owner | Buy | 5,000 | 4.05 | $20,250 | 10,534,358 | Form 4 |
| 2026-05-19 | Chernett Jorey10% owner | Buy | 30,000 | 4.09 | $122,700 | 10,529,358 | Form 4 |
| 2026-04-16 | Kaushal MohitDirector | Saleplan | 38,433 | 3.50 | $134,516 | 172,583 | Form 4 |
| 2026-04-14 | Kaushal MohitDirector | Saleplan | 57,286 | 3.50 | $200,501 | 211,016 | Form 4 |
| 2026-04-09 | Chernett Jorey10% owner | Buy | 20,000 | 3.10 | $62,000 | 10,499,358 | Form 4 |
| 2026-03-27 | Chernett Jorey10% owner | Buy | 27,429 | 2.96 | $81,190 | 10,479,358 | Form 4 |
| 2026-03-26 | Chernett Jorey10% owner | Buy | 50,000 | 3.15 | $157,500 | 10,451,929 | Form 4 |
| 2026-03-24 | Chernett Jorey10% owner | Buy | 125,000 | 3.11 | $388,750 | 10,401,929 | Form 4 |
| 2026-03-20 | Chernett Jorey10% owner | Buy | 25,000 | 3.35 | $83,750 | 10,276,929 | Form 4 |
| 2026-03-17 | Chernett Jorey10% owner | Buy | 75,000 | 3.42 | $256,500 | 10,251,929 | Form 4 |
| 2026-03-16 | Chernett Jorey10% owner | Buy | 60,985 | 3.29 | $200,641 | 10,176,929 | Form 4 |
| 2026-03-13 | Chernett Jorey10% owner | Buy | 263,000 | 2.92 | $767,960 | 10,115,944 | Form 4 |
| 2026-01-02 | Carter Robert RossChief Financial Officer | Sale | 247 | 3.56 | $879 | 235,122 | Form 4 |
| 2025-12-15 | Hively BradDirector | Sale | 13,333 | 3.77 | $50,265 | 683,721 | Form 4 |
| 2025-11-18 | Pacala Mark LDirector | Sale | 2,160 | 4.00 | $8,640 | 222,811 | Form 4 |
| 2025-11-18 | Pacala Mark LDirector | Sale | 1,210 | 4.00 | $4,840 | 221,601 | Form 4 |
| 2025-11-18 | Pacala Mark LDirector | Sale | 46,630 | 4.00 | $186,520 | 174,971 | Form 4 |
| 2025-09-04 | M33 Growth I L.P.Director, 10% ownerwith Toi M, LLC, M33 Growth I GP LLC | Sale | 6,018,168 | 3.09 | $18.60M | 7,932,389 | Form 4 |
| 2025-09-04 | M33 Growth I L.P.Director, 10% ownerwith Toi M, LLC, M33 Growth I GP LLC | Saleindirect | 681,832 | 3.09 | $2.11M | 590,892 | Form 4 |
| 2025-08-19 | Hively BradDirector | Sale | 20,221 | 4.06 | $82,097 | 622,980 | Form 4 |
| 2025-06-05 | M33 Growth I L.P.Director, 10% ownerwith Toi M, LLC, M33 Growth I GP LLC | Sale | 673,676 | 3.05 | $2.05M | 13,950,557 | Form 4 |
| 2025-06-05 | M33 Growth I L.P.Director, 10% ownerwith Toi M, LLC, M33 Growth I GP LLC | Saleindirect | 76,324 | 3.05 | $232,788 | 1,272,724 | Form 4 |
| 2025-06-03 | Hively BradDirector | Sale | 1,867,605 | 2.87 | $5.36M | 712,033 | Form 4 |
| 2025-06-03 | Hively BradDirector | Sale | 108,532 | 2.87 | $311,487 | 603,501 | Form 4 |
| 2025-05-20 | M33 Growth I L.P.Director, 10% ownerwith Toi M, LLC, M33 Growth I GP LLC | Sale | 1,796,468 | 2.71 | $4.87M | 14,624,233 | Form 4 |
| 2025-05-20 | M33 Growth I L.P.Director, 10% ownerwith Toi M, LLC, M33 Growth I GP LLC | Saleindirect | 203,532 | 2.71 | $551,572 | 1,349,048 | Form 4 |
| 2025-03-26 | Hively BradDirector | Buy | 45,280 | 1.04 | $47,091 | 712,033 | Form 4/A |
| 2025-03-26 | Barasch Richard ADirector | Buyindirect | 1,358,448 | 1.04 | $1.41M | 1,775,641 | Form 4 |
| 2025-03-26 | Carter Robert RossChief Financial Officer | Buy | 9,056 | 1.04 | $9,418 | 39,407 | Form 4 |
| 2025-03-26 | Castle JeremyChief Operating Officer | Buy | 9,056 | 1.04 | $9,418 | 90,386 | Form 4 |
6 more
| 2025-03-26 | Johnson Karen MarieDirector | Buy | 36,224 | 1.04 | $37,673 | 203,409 | Form 4 |
| 2025-03-26 | Pacala Mark LDirector | Buyindirect | 90,562 | 1.04 | $94,184 | 224,971 | Form 4 |
| 2025-03-26 | Podnos YaleChief Medical Officer | Buy | 9,056 | 1.04 | $9,418 | 79,049 | Form 4 |
| 2025-03-26 | Virnich DanielChief Executive Officer | Buy | 22,640 | 1.04 | $23,546 | 724,363 | Form 4 |
| 2024-12-02 | Hively BradDirector | Buy | 50,000 | 0.15 | $7,500 | 666,753 | Form 4 |
| 2024-11-26 | Hively BradDirector | Buy | 250,000 | 0.17 | $42,500 | 616,753 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
46 × grant or award22 × other15 × returned to the company6 × option exercise2 × conversion1 × option exercise1 × shares withheld for tax
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-07-27 | Johnson Karen MarieDirector | Grant or award A | +31,124 | – | 319,410 | Form 4 |
| 2026-07-27 | Hively BradDirector | Grant or award A | +27,108 | – | 710,829 | Form 4 |
| 2026-07-27 | Tzoumakas Kimberly JoDirector | Grant or award A | +29,116 | – | 46,301 | Form 4 |
| 2026-07-27 | Stolper MarkDirector | Grant or award A | +31,124 | – | 56,957 | Form 4 |
| 2026-07-27 | Pacala Mark LDirector | Grant or award A | +30,120 | – | 286,881 | Form 4 |
| 2026-07-27 | McGeorge AnneDirector | Grant or award A | +41,165 | – | 332,535 | Form 4 |
| 2026-07-27 | Kaushal MohitDirector | Grant or award A | +33,133 | – | 205,716 | Form 4 |
| 2026-07-14 | Podnos YaleChief Medical Officer | Option exercise M | +17,974 | 1.87 | 277,501 | Form 4 |
| 2026-07-14 | Podnos YaleChief Medical Officer | Option exercise M | +5,478 | 2.00 | 265,005 | Form 4 |
| 2026-07-07 | Stolper MarkDirector | Grant or award A | +25,833 | – | 25,833 | Form 4 |
| 2026-07-07 | Tzoumakas Kimberly JoDirector | Grant or award A | +17,185 | – | 17,185 | Form 4 |
| 2026-05-21 | Carter Robert RossChief Financial Officer | Other J | −1,604 | 4.47 | 414,801 | Form 4 |
| 2026-05-21 | Virnich DanielChief Executive Officer | Other J | −23,058 | 4.47 | 2,337,166 | Form 4 |
| 2026-05-21 | Podnos YaleChief Medical Officer | Other J | −1,805 | 4.47 | 282,978 | Form 4 |
| 2026-03-27 | Virnich DanielChief Executive Officer | Grant or award A | −670,608 | – | 2,458,758 | Form 4 |
| 2026-03-27 | Virnich DanielChief Executive Officer | Other J | −98,534 | 3.07 | 2,360,224 | Form 4 |
| 2026-03-27 | Carter Robert RossChief Financial Officer | Grant or award A | −202,914 | – | 436,725 | Form 4 |
| 2026-03-27 | Carter Robert RossChief Financial Officer | Other J | −20,320 | 3.07 | 416,405 | Form 4 |
| 2026-03-27 | Podnos YaleChief Medical Officer | Grant or award A | +66,446 | – | 300,956 | Form 4 |
| 2026-03-27 | Podnos YaleChief Medical Officer | Other J | −16,173 | 3.07 | 284,783 | Form 4 |
| 2026-03-27 | England KristinChief Administrative Officer | Grant or award A | +55,743 | – | 153,780 | Form 4 |
| 2026-03-27 | Langsam JeffreyChief Clinical Officer | Grant or award A | +70,270 | – | 127,650 | Form 4 |
| 2026-03-17 | Podnos YaleChief Medical Officer | Other J | −3,420 | 3.59 | 234,510 | Form 4 |
| 2026-03-17 | Carter Robert RossChief Financial Officer | Other J | −1,314 | 3.59 | 233,811 | Form 4 |
| 2026-03-17 | Virnich DanielChief Executive Officer | Other J | −11,834 | 3.59 | 1,788,150 | Form 4 |
| 2026-01-02 | Carter Robert RossChief Financial Officer | Other J | −244 | 3.67 | 235,125 | Form 4/A |
| 2025-11-20 | Hively BradDirector | Grant or award A | +41,667 | – | 664,647 | Form 4 |
| 2025-11-20 | Hively BradDirector | Grant or award A | +32,407 | – | 697,054 | Form 4 |
| 2025-11-20 | Pacala Mark LDirector | Grant or award A | +46,296 | – | 221,267 | Form 4 |
| 2025-11-20 | Pacala Mark LDirector | Grant or award A | +35,494 | – | 256,761 | Form 4 |
| 2025-11-20 | Johnson Karen MarieDirector | Grant or award A | +47,840 | – | 251,249 | Form 4 |
| 2025-11-20 | Johnson Karen MarieDirector | Grant or award A | +37,037 | – | 288,286 | Form 4 |
| 2025-11-20 | Ling GabrielDirector | Grant or award A | +46,296 | – | 296,502 | Form 4 |
| 2025-11-20 | Ling GabrielDirector | Grant or award A | +37,037 | – | 333,539 | Form 4 |
| 2025-11-20 | Kaushal MohitDirector | Grant or award A | +50,926 | – | 228,179 | Form 4 |
| 2025-11-20 | Kaushal MohitDirector | Grant or award A | +40,123 | – | 268,302 | Form 4 |
| 2025-11-20 | McGeorge AnneDirector | Grant or award A | +67,901 | – | 251,247 | Form 4 |
| 2025-11-20 | McGeorge AnneDirector | Grant or award A | +40,123 | – | 291,370 | Form 4 |
| 2025-11-18 | M33 Growth I L.P.Director | Other J | −590,892 | – | 0 | Form 4 |
| 2025-11-18 | M33 Growth I L.P.Director | Other J | +11,818 | – | 7,944,207 | Form 4 |
| 2025-11-18 | M33 Growth I L.P.Director | Other J | −2,500,000 | – | 5,444,207 | Form 4 |
| 2025-11-18 | Ling GabrielDirector | Other J | +141,149 | – | 250,206 | Form 4 |
| 2025-11-17 | Carter Robert RossChief Financial Officer | Grant or award A | +195 | – | 235,369 | Form 4 |
| 2025-11-17 | Podnos YaleChief Medical Officer | Grant or award A | +2,086 | – | 237,930 | Form 4 |
| 2025-11-17 | Virnich DanielChief Executive Officer | Grant or award A | +6,464 | – | 1,799,984 | Form 4 |
| 2025-11-12 | Podnos YaleChief Medical Officer | Grant or award A | +306 | – | 234,642 | Form 4 |
| 2025-11-12 | Podnos YaleChief Medical Officer | Grant or award A | +1,202 | – | 235,844 | Form 4 |
| 2025-11-12 | Virnich DanielChief Executive Officer | Grant or award A | +6,211 | – | 1,793,520 | Form 4 |
| 2025-07-24 | Barasch Richard ADirector | Other J | −287,756 | – | 2,635,881 | Form 4 |
| 2025-07-22 | England KristinChief Administrative Officer | Grant or award A | +98,037 | – | 98,037 | Form 4 |
| 2025-06-18 | Barasch Richard ADirector | Conversion C | +620,400 | – | 2,555,541 | Form 4 |
| 2025-06-17 | Barasch Richard ADirector | Option exercise X | +679,224 | 1.20 | 3,234,765 | Form 4 |
| 2025-06-17 | Barasch Richard ADirector | Shares withheld for tax F | −311,128 | 2.62 | 2,923,637 | Form 4 |
| 2025-06-17 | Barasch Richard ADirector | Conversion C | +159,500 | – | 1,935,141 | Form 4 |
| 2025-06-03 | Hively BradDirector | Option exercise M | +684,528 | 0.85 | 1,396,561 | Form 4 |
| 2025-06-03 | Hively BradDirector | Option exercise M | +105,320 | 0.48 | 1,501,881 | Form 4 |
| 2025-06-03 | Hively BradDirector | Option exercise M | +131,297 | 1.87 | 1,633,178 | Form 4 |
| 2025-06-03 | Hively BradDirector | Option exercise M | +946,460 | 0.85 | 2,579,638 | Form 4 |
| 2025-05-21 | Langsam JeffreyChief Clinical Officer | Grant or award A | +57,380 | – | 57,380 | Form 4 |
| 2025-05-21 | Castle JeremyChief Operating Officer | Returned to the company D | −5,636 | 2.68 | 247,031 | Form 4 |
| 2025-05-21 | Carter Robert RossChief Financial Officer | Returned to the company D | −1,601 | 2.68 | 235,174 | Form 4 |
| 2025-05-21 | Podnos YaleChief Medical Officer | Returned to the company D | −1,801 | 2.68 | 234,336 | Form 4 |
| 2025-05-21 | Virnich DanielChief Executive Officer | Returned to the company D | −20,388 | 2.68 | 1,787,309 | Form 4 |
| 2025-03-31 | Virnich DanielChief Executive Officer | Grant or award A | +1,083,334 | – | 1,807,697 | Form 4 |
| 2025-03-31 | Castle JeremyChief Operating Officer | Grant or award A | +162,281 | – | 252,667 | Form 4 |
| 2025-03-31 | Carter Robert RossChief Financial Officer | Grant or award A | +197,368 | – | 236,775 | Form 4 |
| 2025-03-31 | Podnos YaleChief Medical Officer | Grant or award A | +157,088 | – | 236,137 | Form 4 |
| 2025-03-26 | M33 Growth I L.P.Director, 10% owner | Grant or award A | +2,716,898 | 1.04 | 16,420,701 | Form 4 |
| 2025-03-19 | Carter Robert RossChief Financial Officer | Returned to the company D | −1,150 | 0.89 | 30,351 | Form 4 |
| 2025-03-19 | Podnos YaleChief Medical Officer | Returned to the company D | −2,975 | 0.89 | 69,993 | Form 4 |
| 2025-03-19 | Virnich DanielChief Executive Officer | Returned to the company D | −10,261 | 0.89 | 701,723 | Form 4 |
| 2025-01-06 | Carter Robert RossChief Financial Officer | Returned to the company D | −258 | 0.34 | 31,501 | Form 4 |
| 2024-12-03 | Castle JeremyChief Operating Officer | Returned to the company D | −1,130 | 0.16 | 81,330 | Form 4 |
| 2024-11-22 | Hively BradDirector | Grant or award A | +44,000 | – | 720,203 | Form 4 |
| 2024-11-22 | Ling GabrielDirector | Grant or award A | +40,000 | – | 109,057 | Form 4 |
| 2024-11-22 | Kaushal MohitDirector | Grant or award A | +56,000 | – | 177,253 | Form 4 |
| 2024-11-22 | Johnson Karen MarieDirector | Grant or award A | +52,000 | – | 167,185 | Form 4 |
| 2024-11-22 | McGeorge AnneDirector | Grant or award A | +56,000 | – | 183,346 | Form 4 |
| 2024-11-22 | Pacala Mark LDirector | Grant or award A | +50,000 | – | 134,409 | Form 4 |
| 2024-11-22 | Barasch Richard ADirector | Grant or award A | +80,000 | – | 417,193 | Form 4 |
| 2024-11-20 | Podnos YaleChief Medical Officer | Returned to the company D | −1,709 | 0.14 | 74,261 | Form 4 |
| 2024-11-20 | Podnos YaleChief Medical Officer | Returned to the company D | −267 | 0.14 | 73,994 | Form 4 |
| 2024-11-20 | Podnos YaleChief Medical Officer | Returned to the company D | −1,026 | 0.14 | 72,968 | Form 4 |
| 2024-11-20 | Carter Robert RossChief Financial Officer | Returned to the company D | −235 | 0.14 | 31,759 | Form 4 |
| 2024-11-20 | Virnich DanielChief Executive Officer | Returned to the company D | −4,750 | 0.14 | 716,961 | Form 4 |
| 2024-11-20 | Virnich DanielChief Executive Officer | Returned to the company D | −4,977 | 0.14 | 711,984 | Form 4 |
| 2024-11-12 | Hively BradDirector | Other J | −353,450 | – | 366,753 | Form 4 |
| 2024-11-12 | Virnich DanielChief Executive Officer | Other J | −78,094 | – | 838,853 | Form 4 |
| 2024-11-12 | Virnich DanielChief Executive Officer | Other J | −117,142 | – | 721,711 | Form 4 |
| 2024-11-12 | Pacala Mark LDirector | Other J | −20,248 | – | 114,781 | Form 4 |
| 2024-11-12 | Pacala Mark LDirector | Other J | −30,372 | – | 84,409 | Form 4 |
| 2024-11-12 | Podnos YaleChief Medical Officer | Other J | −11,359 | – | 93,009 | Form 4 |
| 2024-11-12 | Podnos YaleChief Medical Officer | Other J | −17,039 | – | 75,970 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.